Neumedicines Inc.   Report issue

For profit Phase 2
Founded: Pasadena CA United States (2003)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2012
NCT01742221
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

interleukin-12 (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Radiation Syndrome (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Mycoses (Phase 2)

Mycosis Fungoides (Phase 2)

Radiation Injuries (Phase 2)

Sezary Syndrome (Phase 2)

Surgical Wound (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 1